Interview: Quintiles India CEO on green shoots, digital patients & white noise
This article was originally published in Scrip
Executive Summary
Naz Haji, Quintiles' new country CEO for India, claims there are green shoots in India's beleaguered clinical research segment. Sponsors, he says, are beginning to reassess decisions to move studies away from the country, although he admits the confidence gap may take a while to bridge.
You may also be interested in...
Pre-work Rigour, 'Clean' Documentation Key As FDA Unlocks Remote Inspection Tools
A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.
Boehringer Ingelheim’s Formula For Scaling Transformation, Digitization
Boehringer Ingelheim’s corporate senior vice president, head of global regions, Timmo Rousku Andersen, outlines at a recent summit the company’s reshaped approach to digital innovation and the need to entrench an execution bias to scale transformation initiatives.
'Incorrect' To Assume Interchangeables Are Safer, More Effective Than Biosimilars, Says FDA
US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.